ReViral, a clinical-stage biopharmaceutical company focused on discovering and developing antiviral therapeutics that target (RSV) respiratory syncytial virus has confirmed the FDA has granted Fast Track designation to Sisunatovir.

Sisunatovir is orally administered and is for the treatment of patients with serious RSV infection. Richmond Pharmacology is proud to have supported the development by conducting the First in Human Study earlier in the drug development.

RSV affects approximately 64 million people and causes approximately 160,000 deaths each year. Fast Track is a process intended to facilitate the development and expediate the review of drug candidates that treat serious conditions and fill an unmet medical need.

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event